Efficacy and Safety of Topiramate in Pediatric Migraine

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001635

Enrollment

Unknown

Registered

2011-10-23

Start date

2009-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Migraine

Interventions

3:Topiramate

1:Ginkgo Biloba Extrai

Eligibility

Sex/Gender

All

Age

5 Years to 18 Years

Inclusion criteria

Inclusion criteria: Eligible participants in the study will be children of either sex, 8 to 12 years of age, with a history of migraine for 3 months and with no any treatment before recruited in the study. They will be diagnosed as having migraine with or without aura, according to 2004 International Headache Society criteria for migraine.

Exclusion criteria

Exclusion criteria: other diseases of the nervous system, such as epilepsy.

Design outcomes

Primary

Measure	Time frame
Monthly Migraine Attack Rate;Duration of Migraine Episode and Migraine Degree;Adverse event;	—

Countries

China

Contacts

Public ContactNong Xiao

xiaonongwl@163.com+86 18983665866

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026